Cost effectiveness of ramipril in patients with non-diabetic nephropathy and hypertension: economic evaluation of ramipril efficacy in nephropathy (REIN) study for Germany from the perspective of statutory health insurance

The requested reference [460244670d460b71541136523a427442b0075588] no longer exists in our database. It has been replaced by the current reference: [e0c2e94bbb7f007dda20dde18c7c667b4f6671cd]

Authors
Category Primary study
Year 2001
This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. The authors argued that adding ramipril to conventional treatment of hypertension in patients with non-diabetic nephropathy (proteinuria of over 3.0 g per day) was cost-effective.
Epistemonikos ID: 96485a38548bc3fb9eeb30e51af206a6f53a5c70
First added on: Apr 19, 2023